|
385
|
| 1606 |
ADAM17
|
|
affects_quantity of
|
TNF
|
in TLR2 stimulated murine microglial cell line BV-2; if SOD1(G93A) is overexpressed
|
|
19091752
|
Amyotrophic lateral sclerosis
|
|
937
|
| 5739 |
ADAM17
|
NOT |
affects_activity of
|
Alpha-secretase
|
if EGCG-mediated
|
|
16624814
|
Alzheimer disease
|
|
2,351
|
| 20580 |
NGF
|
|
increases_expression of
|
ADAM17
|
|
|
21321391
|
Alzheimer disease
|
|
2,623
|
| 25106 |
ADAM17
|
|
affects_processing of
|
NOTCH1
|
|
| 25108 |
TIMP1
|
NOT |
decreases_activity of
|
ADAM17
|
|
| 25109 |
TIMP3
|
|
decreases_activity of
|
ADAM17
|
|
| 25111 |
12-O-Tetradecanoylphorbol 13-acetate
|
|
affects_activity of
|
ADAM17
|
leading to the isomerization of disulfide bonds in ADAM17
|
| 25112 |
p38 MAPK
|
|
increases_phosphorylation of
|
ADAM17
|
if p38 is activated
|
|
21413990
|
Alzheimer disease
|
|
2,673
|
| 25205 |
ADAM17
|
NOT |
affects_processing of
|
APLP2
|
BACE1 cleaves after leucine 659.
|
|
21695060
|
Alzheimer disease
|
|
2,708
|
| 25282 |
12-O-Tetradecanoylphorbol 13-acetate
|
|
increases_activity of
|
ADAM17
|
|
| 25283 |
ADAM17
|
|
affects_processing of
|
APP
|
after PMA stimulation, independently of ADAM10
|
|
20676056
|
Alzheimer disease
|
|
2,928
|
| 26782 |
CD9
|
|
interacts (colocalizes) with
|
ADAM17
|
on the surface of endothelial and monocytic cells
|
| 26783 |
CD9
|
|
affects_activity of
|
ADAM17
|
|
|
21365281
|
Alzheimer disease
|
|
3,219
|
| 29723 |
IL1B
|
|
increases_expression of
|
ADAM17
|
|
| 29728 |
TAPI-2
|
|
decreases_activity of
|
ADAM17
|
|
|
18021299
|
Alzheimer disease
|
|
3,761
|
| 36959 |
ADAM17
|
|
affects_quantity of
|
TNF
|
via releasing TNF-alpha from cell membranes
|
|
22970774
|
Alzheimer disease
|
|
5,085
|
| 49946 |
FLT3-ITD
|
|
increases_expression of
|
ADAM17
|
|
|
16270043
|
Acute promyelocytic leukemia
|
|
8,033
|
| 80026 |
TIMP3
|
|
affects_activity of
|
ADAM17
|
|
|
15760767
|
Atherosclerosis
|
|
8,411
|
| 85761 |
ADAM17
|
|
increases_activity of
|
non-amyloidogenic pathway
|
|
|
26993302
|
Alzheimer disease
Metabolic
|
|
8,431
|
| 85962 |
Alzheimer disease
|
|
increases_expression of
|
ADAM17
|
in AD brain
|
|
27333034
|
Alzheimer disease
|
|
9,791
|
| 103524 |
TRIM37
|
|
affects_expression of
|
ADAM17
|
in osteosarcoma cell lines
|
|
29163677
|
Cancer
Mulibrey nanism
|
|
10,298
|
| 107012 |
Melatonin
|
|
affects_expression of
|
ADAM17
|
at the transcriptional level
|
|
28294066
|
Alzheimer disease
|
|
10,949
|
| 111446 |
ADAM17
|
|
increases_processing of
|
TREM2
|
resulting in soluble TREM2 (sTREM2)
|
| 111448 |
ADAM17
|
|
increases_quantity of
|
TREM2, soluble
|
via shedding of TREM2 by the protease
|
| 143842 |
ADAM17
|
|
increases_activity of
|
TREM2 ectodomain proteolysis
|
via shedding of TREM2 by the protease
|
|
30127720
|
Neurological
Alzheimer disease
|
|
11,676
|
| 116977 |
SARS-CoV S protein
|
|
increases_activity of
|
ADAM17
|
if SARS-S is bound to ACE2
|
| 117211 |
ADAM17
|
|
decreases_quantity of
|
ACE2
|
via proteolytic processing
|
| 117212 |
ADAM17
|
|
affects_activity of
|
TMPRSS2
|
|
| 117762 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
|
24227843
|
Immunological
SARS-CoV infection
|
|
11,748
|
| 116388 |
ADAM17
|
|
affects_activity of
|
ACE2
|
via proteolysis
|
| 116392 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolysis
|
| 116393 |
Angiotensin II
|
|
increases_activity of
|
ADAM17
|
|
| 116481 |
ADAM17
|
|
increases_activity of
|
Notch signaling pathway
|
|
|
32333398
|
COVID-19
|
|
11,841
|
| 116917 |
SARS-CoV-2 S protein
|
|
increases_activity of
|
ADAM17
|
|
| 116918 |
ADAM17
|
|
increases_processing of
|
ACE2
|
via proteolytic cleavage
|
| 116921 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic cleavage
|
| 116931 |
ADAM17
|
|
decreases_quantity of
|
ACE2, membrane-bound
|
via proteolytic cleavage
|
|
32264791
|
COVID-19
SARS-CoV infection
|
|
11,846
|
| 121046 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in primary human airway epithelial cells
|
|
19411314
|
SARS-CoV infection
|
|
11,847
|
| 116976 |
SARS-CoV S protein
|
|
increases_activity of
|
ADAM17
|
after binding to ACE2
|
| 133145 |
ADAM17
|
|
increases_quantity of
|
SARS-CoV
|
|
| 133147 |
ADAM17
|
|
increases_activity of
|
TNF
|
|
|
18490652
|
SARS-CoV infection
|
|
11,899
|
| 117239 |
AGTR1
|
|
increases_activity of
|
ADAM17
|
in cerebrospinal fluid; during the development of DOCA-salt hypertension
|
| 132922 |
hypertension
|
|
increases_quantity of
|
ADAM17
|
in cerebrospinal fluid
|
|
28512108
|
Neurological
SARS-CoV infection
|
|
11,902
|
| 117160 |
AGTR1
|
|
increases_activity of
|
ADAM17
|
in the hypothalamus ; during DOCA-salt hypertension
|
|
28512108
|
Neurological
|
|
11,924
|
| 117260 |
AGTR1
|
|
increases_activity of
|
ADAM17
|
in myocardium
|
| 133118 |
ADAM17
|
|
decreases_quantity of
|
ACE2
|
in myocardium
|
| 133119 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
|
24332999
|
Endocrine
|
|
12,185
|
| 119545 |
AGTR1
|
|
increases_activity of
|
ADAM17
|
|
| 119546 |
ADAM17
|
|
increases_activity of
|
EGFR
|
|
| 119547 |
ADAM17
|
|
increases_activity of
|
TNF
|
via maturation of TNF ligands
|
| 119550 |
ADAM17
|
|
decreases_quantity of
|
IL6R
|
|
| 119551 |
ADAM17
|
|
decreases_quantity of
|
sIL6R
|
|
|
32325025
|
COVID-19
|
|
12,186
|
| 119558 |
ADAM17
|
|
increases_activity of
|
TNF
|
by proteolytic processing of the precursor TNF-alpha
|
|
9034191
|
Inflammation
|
|
12,207
|
| 119890 |
ADAM17
|
|
affects_activity of
|
ACE2
|
via proteolytic cleavage
|
|
32294179
|
Diabetes mellitus, type II
Insulin resistance
COVID-19
|
|
12,272
|
| 120379 |
PACS2
|
|
affects transport of
|
ADAM17
|
regulator of ADAM17 trafficking
|
| 120380 |
decreased PACS2 level
|
|
decreases_quantity of
|
ADAM17
|
reducing ADAM17 cell-surface levels
|
| 120381 |
PACS2
|
|
interacts (colocalizes) with
|
ADAM17
|
on early endosomes
|
| 120384 |
decreased PACS2 level
|
|
decreases_activity of
|
ADAM17
|
reducing ADAM17-dependent ErbB ligand shedding
|
| 120387 |
PACS2
|
|
increases_quantity of
|
ADAM17
|
PACS-2 loss reduces ADAM17 cell-surface levels
|
| 120388 |
PACS2
|
|
increases_activity of
|
ADAM17
|
PACS-2 loss reduces ADAM17-dependent ErbB ligand shedding
|
| 120393 |
RHBDF1
|
|
affects_activity of
|
ADAM17
|
|
| 120394 |
RHBDF2
|
|
affects_activity of
|
ADAM17
|
|
| 120395 |
FURIN
|
|
affects_activity of
|
ADAM17
|
|
|
26108729
|
Metabolic
|
|
12,274
|
| 120389 |
PACS2
|
|
increases_activity of
|
ADAM17
|
on early endosome; stabilizing a pool of the metalloproteinase ADAM17
|
| 120390 |
decreased PACS2 level
|
|
increases_transport of
|
ADAM17
|
to lysosomes; reducing ErbB shedding
|
| 120391 |
PACS2-phosSer437
|
|
interacts (colocalizes) with
|
ADAM17
|
on early endosome; Akt-phosphorylated pSer437-PACS-2, mediating delivery of the protease to the cell surface
|
| 120398 |
PACS2-phosSer437
|
|
increases_transport of
|
ADAM17
|
to the cell surface; when PACS2 is phosphorylated by Akt
|
|
28476937
|
Metabolic
|
|
12,330
|
| 120866 |
ADAM17
|
|
decreases_activity of
|
ACE2
|
|
| 120867 |
Angiotensin II
|
|
increases_expression of
|
ADAM17
|
|
| 120868 |
ACE2
|
|
decreases_expression of
|
ADAM17
|
|
|
23893738
|
Diabetes mellitus, type II
Insulin resistance
|
CIDeRplus